First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using 89Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer
Conclusion: This first-in-human study demonstrated safety, dosimetry, biodistribution, and successful HER2-targeted imaging with 89Zr-pertuzumab PET/CT. Potential clinical applications include assessment of the HER2 status of lesions that may not be accessible to biopsy and assessment of HER2 heterogeneity.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Ulaner, G. A., Lyashchenko, S. K., Riedl, C., Ruan, S., Zanzonico, P. B., Lake, D., Jhaveri, K., Zeglis, B., Lewis, J. S., ODonoghue, J. A. Tags: Clinical Source Type: research
More News: Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | Cardiology | Clinical Trials | Heart | HER2 | Liver | Neurology | Nuclear Medicine | Study | Toxicology | Urology & Nephrology